A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-23

Study Completion Date

2017-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this POC clinical study is to investigate the impact of the test product (Developmental Cosmetic Moisturising Cream) on skin barrier function and skin moisturisation on the forearm and face after 4 weeks of twice daily application compared to no treatment in participants with dry sensitive skin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function

NCT03804710

Dry Skin Skin Care

COMPLETED NA

Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction

NCT07183423

Psoriasis Atopic Dermatitis Xerosis +1 more

RECRUITING NA

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis

NCT05807113

Atopic Diathesis Eczema-prone Skin

COMPLETED NA

CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis

NCT07204561

Atopic Dermatitis (AD)

RECRUITING NA

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis

NCT05786976

Atopic Diathesis Eczema-Prone Skin

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Areas on the volar forearm and each side of the face, will be selected for measurements of transepidermal water loss (TEWL) and corneometry to be conducted . A physical challenge and a regression period of 5 days is also included to evaluate skin barrier function and moisturisation.

A regression period of 5 days (Days 30, 31, 32, 33 and 34) of no study product use following the 4 week treatment phase is also included to evaluate skin barrier function and moisturisation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test product/ No treatment

Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.

Group Type OTHER

Test product (Moisturising cream)

Intervention Type OTHER

Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

No treatment

Intervention Type OTHER

No treatment.

Test product/positive control

Participants randomized to this arm will apply Test and positive product at allocated sites.

Group Type OTHER

Test product (Moisturising cream)

Intervention Type OTHER

Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Positive control (Commercial market place moisturising cream)

Intervention Type OTHER

Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Positive control /no treatment

Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.

Group Type OTHER

Positive control (Commercial market place moisturising cream)

Intervention Type OTHER

Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

No treatment

Intervention Type OTHER

No treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test product (Moisturising cream)

Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Intervention Type OTHER

Positive control (Commercial market place moisturising cream)

Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).

Intervention Type OTHER

No treatment

No treatment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
* Good general and mental health with, in the opinion of the investigator or medically qualified designee no clinically significant and relevant abnormalities in medical history or upon physical examination.
* Self-reported dry, sensitive skin on the face and body.
* Agreement to comply with the procedures and requirements of the study and to attend the scheduled assessment visits.
* Trained examiner visual grading assessment score (including subject self-assessment of tightness) of overall dryness ≥ 3 with a score of at least 1 in the roughness parameter and 4 (for any individual parameter) on each of the forearms and each side of the face at the Screening visit (Visit 1) and Baseline visit (Visit 2).
* In addition, there will be no greater than 0.5 point difference between trained examiner visual grading scores of each volar forearm and each side of the face at the Screening and Baseline visits.
* Fitzpatrick skin type I-IV

Exclusion Criteria

* Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
* Women who are breast-feeding.
* Any history of significant dermatological diseases or conditions or medical conditions known to alter skin appearance or physiologic response (e.g. diabetes) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluations.
* Presence of open sores, pimples, or cysts at the application site.
* Active dermatosis (local or disseminated) that might interfere with the results of the study.
* Considered immune compromised.
* Currently using any medication which in the opinion of the investigator, may affect the evaluation of the study product, or place the subject at undue risk.
* Use of the following topical or systemic medications: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs, and corticosteroids up to 2 weeks before screening visit.
* Intention of using any oral or topical steroids.
* Regular use of inhaled steroids (occasional use is permitted).
* Regular use of topical anti-itch medications (occasional use permitted; the product should be applied with an applicator but not to the proposed application areas.
* Use of any topical drug or medication in the proposed application areas.
* Intention of being vaccinated during the study period or has been vaccinated within 3 weeks of the screening visit.
* Currently receiving allergy injections, or received an allergy injection within 7 days prior to Visit 1, or expects to begin injections during study participation.
* Previous history of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, cosmetics or medication.
* Known or suspected intolerance or hypersensitivity to any of the study materials (or closely related compounds) or any of their stated ingredients.
* Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 14 days of the screening visit.
* Previous participation in this study.
* Recent history (within the last 5 years) of alcohol or other substance abuse.
* Smoker (including e-cigarettes)
* Moles, tattoos, scars, hairs, etc. at the test areas if it is likely that they could affect the assessments.
* Subject has visible sunburn on the test sites.
* Use of self-tanning products on the test areas (face and arms) within 2 weeks prior to the screening visit.
* Any individual parameter score 4 on any test areas of the face or either of the forearms as assessed by a trained examiner.
* Any Subject who, in the judgment of the Investigator, should not participate in the study.
* An employee of the sponsor or the study site or members of their immediate family.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes